Neurology · DepressionRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for SPRAVATO (Esketamine) by Janssen

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen18 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 6:31:06 AM

Assessment confidence: 55% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's acceptance of the supplemental application for SPRAVATO is a significant regulatory milestone that could strengthen Janssen's competitive position in the neurology and depression treatment sectors. This development warrants close monitoring as it may influence market dynamics and competitor strategies. Regulatory context from FDA (FDA AP — SPRAVATO (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this supplement on market dynamics and competitive positioning. The strongest clinical anchor is Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Depression, 7 regulatory and 5 competitive items passed relevance filtering for Janssen.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This acceptance may enhance Janssen's position in the depression treatment market, potentially impacting competitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SPRAVATO (SUPPL) (FDA). Entity match (janssen). Relevant agencies in corpus: FDA, MHRA. The acceptance of this supplemental application indicates a potential for expanded indications or labeling, which could enhance compliance and market access for SPRAVATO.

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, SPRAVATO could capture additional market share in the depression treatment market, impacting revenue streams for both Janssen and its competitors.
Upside for Janssen may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the implications of this supplement on market dynamics and competitive positioning.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval process and any subsequent market actions by competitors.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SPRAVATO (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
FDA AP — SPRAVATO (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
FDA AP — SPRAVATO (SUPPL)
FDAhigh relevance
Entity match (janssen)
FDA document
View source
Data Standards Program Strategic Plan and Board
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: PALSONIFY
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Notice: Register of authorised online sellers of medicines in Northern Ireland
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
PDN Post Market, Multicenter, Prospective, Global Clinical Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Supplemental Application for AJOVY (Fremanezumab)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalsmedium relevance
Moderate corpus alignment

Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Associations between Age, Treatment Modality and Survival in Atypical Meningioma: Analysis of the SEER Database, 2000-2021.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
SPRAVATO
depression treatment market

Commercial impact

medium

If approved, SPRAVATO could capture additional market share in the depression treatment market, impacting revenue streams for both Janssen and its competitors.

Regulatory impact

medium

The acceptance of this supplemental application indicates a potential for expanded indications or labeling, which could enhance compliance and market access for SPRAVATO.

What to watch

Monitor for further updates on the approval process and any subsequent market actions by competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.